Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.47 |
| ▸ | FABP6 | P51161 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27982016 | 0.92 | ALDH1A1 (0.47) | ALDH1A1RAB9AKDM4EPOLBL3MBTL1 | |
| SCHEMBL29967465 | 0.84 | TDP1 (0.54) | ALDH1A1RAB9AKDM4EPOLBL3MBTL1 | |
| SCHEMBL11144403 | 0.84 | TDP1 (0.54) | ALDH1A1RAB9AKDM4EPOLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL10584298 | 0.83 | TDP1 (0.53) | ALDH1A1RAB9AKDM4EPOLBL3MBTL1 | |
| SCHEMBL10584287 | 0.81 | ALDH1A1 (0.46) | ALDH1A1RAB9AKDM4EKMT2AHPGD | |
| SCHEMBL8764992 | 0.81 | RAB9A (0.58) | ALDH1A1RAB9AKDM4EPOLBL3MBTL1 | |
| SCHEMBL15689338 | 0.78 | NPSR1 (0.46) | ALDH1A1RAB9AL3MBTL1MEN1KMT2A | |
| SCHEMBL14783907 | 0.78 | NPSR1 (0.62) | ALDH1A1RAB9AKDM4EPOLBMEN1 | |
| SCHEMBL29967657 | 0.78 | TDP1 (0.54) | ALDH1A1RAB9AKDM4EPOLBL3MBTL1 | |
| SCHEMBL1574747 | 0.78 | TDP1 (0.54) | ALDH1A1RAB9AKDM4EPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856236-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2018-01-02 | — | — | US | disclosed |
| US-9290478-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-03-22 | — | — | US | disclosed |
| US-9290478-B2 | Substituted quinoxalines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2016-02-04 | — | — | US | disclosed |
| US-9145394-B2 | — | — | 2015-09-29 | — | — | US | disclosed |
| US-9145394-B2 | — | — | 2015-09-29 | — | — | US | disclosed |
| EP-2646432-B1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012073017-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031856-A1 | SUBSTITUTED QUINOXALINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR3, ABL1 | ALDH1A1 2079/4885RAB9A 1127/4885KDM4E 650/4885 |
| US-20130267525-A1 | SUBSTITUTED BENZOPYRAZIN DERIVATIVES AS FGFR KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | FGFR1, FGFR4, FGFR3 | ALDH1A1 1649/4885RAB9A 2600/4885KDM4E 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.